Roche/Genentech CMO Levi Garraway
December 14, 2021 09:00 AM EST
R&D

ASH: Roche's an­ti­body-drug con­ju­gate Po­livy added to chemo-an­ti­body com­bo boosts sur­vival in ear­ly-stage lym­phoma

Kyle Blankenship

Break­throughs in drug de­vel­op­ment have be­gun to un­lock the po­ten­tial of an­ti­body-drug con­ju­gates, ther­a­pies de­signed to bet­ter tar­get pro­teins on tu­mor cells. Genen­tech’s Po­livy has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times